However, due to the effectiveness of clinical first-line treatment, the complexity of autoimmune targets, the side effects of related biological agents and other factors, current clinical progress of targeting CD4+ T-cell subsets in the treatment of AIH is still poor. This evidence concerns the gene CD4 and autoimmune hepatitis.